Intelligence / Healthtech / New Clinical Trials / Dexa Medica Group
Clinicaltrial registered16 Nov 2026
Dexa Medica Group
16 Nov 2026: Trial registered · The Efficacy and Safety of DLBS1442 in Patients With Primary Dysmenorrhea. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 16 Nov 2026
- Title
- The Efficacy and Safety of DLBS1442 in Patients With Primary Dysmenorrhea
- Conditions
- Primary Dysmenorrhea
- Phase
- Phase 2, Phase 3
- Study Type
- Interventional
- Status
- Recruiting
- Countries
- Indonesia
- Country
- Indonesia
- Reference
- NCT07937462
- Location
- Indonesia
What this signal means
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at Dexa Medica Group
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for Dexa Medica Group in our registers.
16 NovDexa Medica Grouptrial registered · HealthtechClinical16 NovDexa Medica Grouptrial registered · HealthtechClinical
More from Indonesia
New Clinical Trials
17 NovPT Equilab Internationaltrial registered · Nutritional Status Evaluation in Underweight Indonesian Children Receiving 0.89 kcal/mL Milk Powder - Site ManadoClinical17 NovPT Equilab Internationaltrial registered · Nutritional Status Evaluation in Underweight Indonesian Children Receiving 0.89 kcal/mL Milk Powder - Site MakassarClinical16 NovDexa Medica Grouptrial registered · Bioequivalence Study of Sitagliptin/Metformin 50 mg/1000 mg Extended Release TabletClinical16 NovDexa Medica Grouptrial registered · The Efficacy and Safety of DLBS3233 in Adults With PrediabetesClinical10 NovPT Bio Farmatrial registered · Cy-Tb for Detecting Mycobacterium Tuberculosis Infection in Indonesian PopulationClinical
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.